Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yohei Sekino

Showing results (21-30 of 119) with videos related to

Pageof 12
Sort By:
BMC Cancer|June 27, 2021
Clinicopathologic features of TDO2 overexpression in renal cell carcinomaQuoc Thang Pham, Daiki Taniyama, Yohei Sekino, et al.
Pathology International|October 1, 2020
Clinicopathological significance of intelectin-1 in colorectal cancer: Intelectin-1 participates in tumor suppression and favorable progressNarutaka Katsuya, Kazuhiro Sentani, Yohei Sekino, et al.
Anticancer Research|May 29, 2017
The Expression of BTS-2 Enhances Cell Growth and Invasiveness in Renal Cell CarcinomaQuoc Thang Pham, Naohide Oue, Yuji Yamamoto, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|July 13, 2022
Minichromosome Maintenance 4 Is Associated with Cancer Stemness and Poor Survival of Patients with Gastric CancerNarutaka Katsuya, Akira Ishikawa, Aya Kido, et al.
International Cancer Conference Journal|September 9, 2020
Primary adenocarcinoma of the rete testis with elevated serum CA19-9 antigen levelsHiroyuki Kitano, Kazuhiro Sentani, Keisuke Goto, et al.
The Prostate|October 17, 2018
Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patientsYohei Sekino, Naohide Oue, Shoichiro Mukai, et al.
World Journal of Urology|February 13, 2026
TROP2 expression is associated with early stage and favorable prognosis in upper tract urothelial carcinomaGo Kobayashi, Yohei Sekino, Tetsutaro Hayashi, et al.
Scientific Reports|July 1, 2026
Clinical and genomic characteristics of primary resistant disease to first-line immuno-oncology plus VEGFR inhibitor therapy in metastatic renal cell carcinomaKohei Kobatake, Keisuke Goto, Yohei Sekino, et al.
Oncology Reports|March 14, 2019
Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancerYohei Sekino, Naoya Sakamoto, Akira Ishikawa, et al.
International Journal of Molecular Sciences|August 16, 2019
TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate CancerYohei Sekino, Xiangrui Han, Takafumi Kawaguchi, et al.
Pageof 12

Showing results (21-30 of 119) with videos related to

Sort By:
Pageof 12
BMC Cancer|June 27, 2021
Clinicopathologic features of TDO2 overexpression in renal cell carcinomaQuoc Thang Pham, Daiki Taniyama, Yohei Sekino, et al.
Pathology International|October 1, 2020
Clinicopathological significance of intelectin-1 in colorectal cancer: Intelectin-1 participates in tumor suppression and favorable progressNarutaka Katsuya, Kazuhiro Sentani, Yohei Sekino, et al.
Anticancer Research|May 29, 2017
The Expression of BTS-2 Enhances Cell Growth and Invasiveness in Renal Cell CarcinomaQuoc Thang Pham, Naohide Oue, Yuji Yamamoto, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|July 13, 2022
Minichromosome Maintenance 4 Is Associated with Cancer Stemness and Poor Survival of Patients with Gastric CancerNarutaka Katsuya, Akira Ishikawa, Aya Kido, et al.
International Cancer Conference Journal|September 9, 2020
Primary adenocarcinoma of the rete testis with elevated serum CA19-9 antigen levelsHiroyuki Kitano, Kazuhiro Sentani, Keisuke Goto, et al.
The Prostate|October 17, 2018
Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patientsYohei Sekino, Naohide Oue, Shoichiro Mukai, et al.
World Journal of Urology|February 13, 2026
TROP2 expression is associated with early stage and favorable prognosis in upper tract urothelial carcinomaGo Kobayashi, Yohei Sekino, Tetsutaro Hayashi, et al.
Scientific Reports|July 1, 2026
Clinical and genomic characteristics of primary resistant disease to first-line immuno-oncology plus VEGFR inhibitor therapy in metastatic renal cell carcinomaKohei Kobatake, Keisuke Goto, Yohei Sekino, et al.
Oncology Reports|March 14, 2019
Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancerYohei Sekino, Naoya Sakamoto, Akira Ishikawa, et al.
International Journal of Molecular Sciences|August 16, 2019
TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate CancerYohei Sekino, Xiangrui Han, Takafumi Kawaguchi, et al.
Pageof 12